These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 18814271)

  • 1. Lack of cross-immune reactivity against influenza H5N1 from seasonal influenza vaccine in humans.
    Tang JW; Ngai KL; Chan PK
    J Med Virol; 2008 Nov; 80(11):1992-6. PubMed ID: 18814271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity, safety, and cross-reactivity of an inactivated, adjuvanted, prototype pandemic influenza (H5N1) vaccine: a phase II, double-blind, randomized trial.
    Wu J; Fang HH; Chen JT; Zhou JC; Feng ZJ; Li CG; Qiu YZ; Liu Y; Lu M; Liu LY; Dong SS; Gao Q; Zhang XM; Wang N; Yin WD; Dong XP
    Clin Infect Dis; 2009 Apr; 48(8):1087-95. PubMed ID: 19281330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K; Leroux-Roels I; Hoppenbrouwers K; Kervyn AD; Vandermeulen C; Forgus S; Leroux-Roels G; Pichon S; Kusters I
    J Infect Dis; 2008 Sep; 198(5):642-9. PubMed ID: 18576945
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prior infection with an H1N1 swine influenza virus partially protects pigs against a low pathogenic H5N1 avian influenza virus.
    Van Reeth K; Braeckmans D; Cox E; Van Borm S; van den Berg T; Goddeeris B; De Vleeschauwer A
    Vaccine; 2009 Oct; 27(45):6330-9. PubMed ID: 19840669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seasonal influenza vaccine elicits heterosubtypic immunity against H5N1 that can be further boosted by H5N1 vaccination.
    van Maurik A; Sabarth N; Dacho HS; Brühl P; Schwendinger M; Crowe BA; Noel Barrett P; Kistner O; Keith Howard M
    Vaccine; 2010 Feb; 28(7):1778-85. PubMed ID: 20018265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing antibody but not hemagglutination antibody provides accurate evaluation for protective immune response to H5N1 avian influenza virus in vaccinated rabbits.
    Zhu H; Ding X; Chen X; Yao P; Xu F; Xie R; Yang Z; Liang W; Zhang Y; Li Y; Shen J; He P; Guo Z; Su B; Sun S; Zhu Z
    Vaccine; 2011 Jul; 29(33):5421-3. PubMed ID: 21645575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.
    Sandbulte MR; Jimenez GS; Boon AC; Smith LR; Treanor JJ; Webby RJ
    PLoS Med; 2007 Feb; 4(2):e59. PubMed ID: 17298168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of cross-neutralizing antibody against H5N1 virus after vaccination with seasonal influenza vaccine in COPD patients.
    Kositanont U; Wongsurakiat P; Pooruk P; Maranetra N; Puthavathana P
    Viral Immunol; 2010 Jun; 23(3):329-34. PubMed ID: 20565296
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T; Richmond PC; Formica NT; Höschler K; Skeljo MV; Stoney T; McVernon J; Hartel G; Sawlwin DC; Bennet J; Ryan D; Basser RL; Zambon MC
    Vaccine; 2008 Nov; 26(50):6383-91. PubMed ID: 18801398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages.
    Camilloni B; Neri M; Lepri E; Iorio AM
    Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
    Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
    Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody persistence after 2-dose priming and booster response to a third dose of an inactivated, adjuvanted, whole-virion H5N1 vaccine.
    Lin JT; Li CG; Wang X; Su N; Liu Y; Qiu YZ; Yang M; Chen JT; Fang HH; Dong XP; Yin WD; Feng ZJ
    J Infect Dis; 2009 Jan; 199(2):184-7. PubMed ID: 19067606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elicitation of protective immune responses using a bivalent H5N1 VLP vaccine.
    Crevar CJ; Ross TM
    Virol J; 2008 Oct; 5():131. PubMed ID: 18957098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Production of H5N1 (NIBRG-14) inactivated whole virus and split virion influenza vaccines and analysis of immunogenicity in mice using different adjuvant formulations.
    Miyaki C; Quintilio W; Miyaji EN; Botosso VF; Kubrusly FS; Santos FL; Iourtov D; Higashi HG; Raw I
    Vaccine; 2010 Mar; 28(13):2505-9. PubMed ID: 20123051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-lasting immunogenicity of a virosomal vaccine in older children and young adults with type I diabetes mellitus.
    Zuccotti GV; Scaramuzza A; Riboni S; Mameli C; Pariani E; Tanzi E; Zanetti A; Radaelli G
    Vaccine; 2009 Aug; 27(39):5357-62. PubMed ID: 19607951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-clade immunogenicity and antigen-sparing with an AS03(A)-adjuvanted prepandemic influenza vaccine in a Thai population.
    Thongcharoen P; Auewarakul P; Hutagalung Y; Ong G; Gillard P; Drame M; Bock HL
    J Med Assoc Thai; 2011 Aug; 94(8):916-26. PubMed ID: 21863672
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of serum neutralization antibodies against seasonal influenza A strain H3N2 and the emerging strains 2009 H1N1 and avian H5N1.
    Zhang R; Rong X; Pan W; Peng T
    Scand J Infect Dis; 2011 Mar; 43(3):216-20. PubMed ID: 21142624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A/Vietnam/1203/2004 (H5N1) vaccine after priming with an antigenic variant.
    Goji NA; Nolan C; Hill H; Wolff M; Noah DL; Williams TB; Rowe T; Treanor JJ
    J Infect Dis; 2008 Sep; 198(5):635-41. PubMed ID: 18694338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of preexisting memory to seasonal A/H1N1 influenza virus on the immune response following vaccination against avian A/H5N1 virus.
    Buricchi F; Bardelli M; Malzone C; Capecchi B; Nicolay U; Fragapane E; Castellino F; Del Giudice G; Galli G; Finco O
    Eur J Immunol; 2013 Mar; 43(3):641-8. PubMed ID: 23238926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Broad cross-protection against H5N1 avian influenza virus infection by means of monoclonal antibodies that map to conserved viral epitopes.
    Chen Y; Qin K; Wu WL; Li G; Zhang J; Du H; Ng MH; Shih JW; Peiris JS; Guan Y; Chen H; Xia N
    J Infect Dis; 2009 Jan; 199(1):49-58. PubMed ID: 19032063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.